# A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B

> **NCT00694785** · PHASE2 · WITHDRAWN · sponsor: **Archemix Corp.** · enrollment: 2 (estimated)

## Conditions studied

- Von Willebrand Disease

## Interventions

- **DRUG:** ARC1779
- **DRUG:** ARC1779
- **DRUG:** ARC1779
- **DRUG:** ARC1779

## Key facts

- **NCT ID:** NCT00694785
- **Lead sponsor:** Archemix Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-10
- **Primary completion:** 2009-06
- **Final completion:** —
- **Target enrollment:** 2 (ESTIMATED)
- **Why stopped:** Sponsor decided not to go forward with the study.
- **Last updated:** 2009-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694785, "A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00694785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*